Literature DB >> 26985057

Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT.

Yong-Il Kim1, Jin Chul Paeng2, Gi Jeong Cheon3, Kyung-Suk Suh4, Dong Soo Lee5, June-Key Chung3, Keon Wook Kang3.   

Abstract

UNLABELLED: (18)F-FDG PET is an effective method of predicting recurrence of hepatocellular carcinoma (HCC) after liver transplantation. We compared recently introduced metabolic and volumetric (18)F-FDG PET/CT indices with the current clinicopathologic predictors for ability to predict recurrence.
METHODS: In total, 110 HCC patients who underwent (18)F-FDG PET and liver transplantation were enrolled. On PET, SUVs and tumor-to-background ratios (TBRs) were measured as metabolic activity indices. Various metabolic tumor volumes and uptake-volume products (UVP) were also measured as volumetric indices. The ability of these indices and other clinicopathologic factors to predict recurrence was compared.
RESULTS: All metabolic and volumetric indices were significant for recurrence prediction on receiver-operating-characteristic curve analyses (P < 0.001). On univariate survival analyses, all PET indices-as well as tumor size, tumor number, the Milan criteria, tumor grade, vascular invasion, and T-stage-were significant factors. However, on multivariate analyses, tumor size, tumor grade, maximum TBR, and UVP calculated by inferior vena cava activity were significant factors (P = 0.004, 0.014, 0.009, and 0.021, respectively). When the Milan criteria and PET factors were included in the multivariate analysis, the Milan criteria (P = 0.029), maximum TBR (P < 0.001), and UVP (P = 0.016) were significant.
CONCLUSION: Volumetric and metabolic activity indices of (18)F-FDG PET are effective predictors of posttransplantation HCC recurrence. In addition to clinicopathologic factors, these indices need to be considered in the selection of candidates for liver transplantation.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  hepatocellular carcinoma; liver transplantation; metabolic tumor volume; positron emission tomography; recurrence

Mesh:

Substances:

Year:  2016        PMID: 26985057     DOI: 10.2967/jnumed.115.170076

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-20       Impact factor: 9.236

2.  An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Wenjie Miao; Pei Nie; Guangjie Yang; Yangyang Wang; Lei Yan; Yujun Zhao; Ting Yu; Mingming Yu; Fengyu Wu; Wei Rao; Zhenguang Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-04       Impact factor: 9.236

3.  Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.

Authors:  Jeong Won Lee; Sang Hyun Hwang; Hyun Jeong Kim; Dongwoo Kim; Arthur Cho; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-11       Impact factor: 9.236

Review 4.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

Review 5.  Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma.

Authors:  Seung Duk Lee; Seong Hoon Kim
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

6.  The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases.

Authors:  Harald Grut; Svein Dueland; Pål Dag Line; Mona Elisabeth Revheim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

7.  Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.

Authors:  Yazan Abuodeh; Arash O Naghavi; Kamran A Ahmed; Puja S Venkat; Youngchul Kim; Bela Kis; Junsung Choi; Benjamin Biebel; Jennifer Sweeney; Daniel A Anaya; Richard Kim; Mokenge Malafa; Jessica M Frakes; Sarah E Hoffe; Ghassan El-Haddad
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

8.  Prognostic value of simultaneous 18F-FDG PET/MRI using a combination of metabolo-volumetric parameters and apparent diffusion coefficient in treated head and neck cancer.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Seo Young Kang; Jin Chul Paeng; Keon Wook Kang; Dong Soo Lee; June-Key Chung
Journal:  EJNMMI Res       Date:  2018-01-10       Impact factor: 3.138

9.  Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma.

Authors:  Paul Blanc-Durand; Axel Van Der Gucht; Adrien Depeursinge; Niklaus Schaefer; Mario Jreige; Marie Nicod-Lalonde; Marina Silva-Monteiro; John O Prior; Alban Denys
Journal:  Oncotarget       Date:  2017-12-19

10.  Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma.

Authors:  Hongping Xia; Jianxiang Chen; Hengjun Gao; Shik Nie Kong; Amudha Deivasigamani; Ming Shi; Tian Xie; Kam M Hui
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.